
Global & Philippines Cancer Therapeutics Market to 2031
Description
The cancer therapeutics market in the Philippines is witnessing growing demand, driven by the introduction of innovative treatments such as targeted therapies, immunotherapies, and biologics. Government efforts, notably through the National Integrated Cancer Control Act and the Philippine Health Insurance Corporation (PhilHealth), have significantly contributed to enhancing access to cancer care services and medications. Despite these advancements, challenges persist—particularly the high cost of therapies and limitations within the country’s healthcare infrastructure—which continue to restrict broader market expansion.
Cancer remains a leading cause of illness and death in the Philippines, with the Philippine Cancer Society reporting over 200,000 new diagnoses annually. In response to this growing burden, the oncology drug market—including chemotherapy, immunotherapy, targeted treatments, and biologics—has seen rapid growth. This transition toward more personalized and advanced therapies is transforming the way cancer is managed in the country.
Alongside the National Integrated Cancer Control Act, PhilHealth has been instrumental in easing the financial burden on patients by incorporating cancer treatment services into its benefit packages. Patients diagnosed with certain cancers can receive partial reimbursements for procedures such as chemotherapy, radiation, and surgery. PhilHealth’s cancer drug program has made vital treatments more accessible to individuals who may otherwise face significant financial barriers, especially in a healthcare system where out-of-pocket expenses are still widespread.
Cancer remains a leading cause of illness and death in the Philippines, with the Philippine Cancer Society reporting over 200,000 new diagnoses annually. In response to this growing burden, the oncology drug market—including chemotherapy, immunotherapy, targeted treatments, and biologics—has seen rapid growth. This transition toward more personalized and advanced therapies is transforming the way cancer is managed in the country.
Alongside the National Integrated Cancer Control Act, PhilHealth has been instrumental in easing the financial burden on patients by incorporating cancer treatment services into its benefit packages. Patients diagnosed with certain cancers can receive partial reimbursements for procedures such as chemotherapy, radiation, and surgery. PhilHealth’s cancer drug program has made vital treatments more accessible to individuals who may otherwise face significant financial barriers, especially in a healthcare system where out-of-pocket expenses are still widespread.
Table of Contents
100 Pages
- 1. Introduction
- 1.1 Report Guidance
- 1.2 Market Segmentation
- 2. Executive Summary
- 2.1 Key Insights
- 3. Research Methodology
- 3.1 Secondary Research
- 3.2 Primary Research
- 3.2.1 Data Triangulation and Validation:
- 4. Philippines Cancer Therapeutics Market Landscape
- 4.1 Overview
- 4.2 Ecosystem Analysis
- 4.2.1 List of Vendors in the Value Chain
- 5. Cancer Therapeutics Market Key Market Dynamics
- 5.1 Cancer Therapeutics Market – Key Market Dynamics
- 5.2 Market Drivers
- 5.3 Market Restraints
- 5.4 Market Opportunities
- 5.5 Future Trends
- 5.6 Impact of Drivers and Restraints
- 6. Philippines Cancer Therapeutics Market – Analysis
- 6.1 Philippines Cancer Therapeutics Market Revenue (US$ Million), 2021–2031
- 6.2 Philippines Cancer Therapeutics Market Revenue and Forecast Analysis
- 7. Philippines Cancer Therapeutics Market Analysis – by Therapy Types
- 7.1 Philippines Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Therapy Types
- 8. Philippines Cancer Therapeutics Market Analysis – by Indications
- 8.1 Philippines Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Indications
- 9. Philippines Cancer Therapeutics Market Analysis – by Distribution Channel
- 9.1 Philippines Cancer Therapeutics Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Distribution Channel
- 10. Competitive Landscape
- 10.1 Heat Map Analysis by Key Players
- 10.1 Company Positioning and Concentration
- 11. Industry Landscape
- 11.1 Overview
- 11.2 Market Initiative
- 11.2 Partnerships and Collaborations
- 11.2 Other Developments
- 12. Company Profiles
- 12.1 Bristol-Myers Squibb Co
- 12.1. 1 Key Facts
- 12.1. 2 Business Description
- 12.1. 3 Products and Services
- 12.1. 4 Financial Overview
- 12.1. 5 SWOT Analysis
- 12.1. 6 Key Developments
- 12.2 AbbVie Inc
- 12.2. 1 Key Facts
- 12.2. 2 Business Description
- 12.2. 3 Products and Services
- 12.2. 4 Financial Overview
- 12.2. 5 SWOT Analysis
- 12.2. 6 Key Developments
- 12.3 Johnson & Johnson
- 12.3. 1 Key Facts
- 12.3. 2 Business Description
- 12.3. 3 Products and Services
- 12.3. 4 Financial Overview
- 12.3. 5 SWOT Analysis
- 12.3. 6 Key Developments
- 12.4 F. Hoffmann-La Roche Ltd
- 12.4. 1 Key Facts
- 12.4. 2 Business Description
- 12.4. 3 Products and Services
- 12.4. 4 Financial Overview
- 12.4. 5 SWOT Analysis
- 12.4. 6 Key Developments
- 12.5 Pfizer Inc
- 12.5. 1 Key Facts
- 12.5. 2 Business Description
- 12.5. 3 Products and Services
- 12.5. 4 Financial Overview
- 12.5. 5 SWOT Analysis
- 12.5. 6 Key Developments
- 12.6 AstraZeneca Plc
- 12.6. 1 Key Facts
- 12.6. 2 Business Description
- 12.6. 3 Products and Services
- 12.6. 4 Financial Overview
- 12.6. 5 SWOT Analysis
- 12.6. 6 Key Developments
- 12.7 Merck KGaA
- 12.7. 1 Key Facts
- 12.7. 2 Business Description
- 12.7. 3 Products and Services
- 12.7. 4 Financial Overview
- 12.7. 5 SWOT Analysis
- 12.7. 6 Key Developments
- 12.8 Novartis AG
- 12.8. 1 Key Facts
- 12.8. 2 Business Description
- 12.8. 3 Products and Services
- 12.8. 4 Financial Overview
- 12.8. 5 SWOT Analysis
- 12.8. 6 Key Developments
- 12.9 Astellas Pharma Inc
- 12.9. 1 Key Facts
- 12.9. 2 Business Description
- 12.9. 3 Products and Services
- 12.9. 4 Financial Overview
- 12.9. 5 SWOT Analysis
- 12.9. 6 Key Developments
- 12.10 Eli Lilly and Co
- 12.10. 1 Key Facts
- 12.10. 2 Business Description
- 12.10. 3 Products and Services
- 12.10. 4 Financial Overview
- 12.10. 5 SWOT Analysis
- 12.10. 6 Key Developments
- 13. Appendix
- 13.1 About Business Market Insights
- 13.2 List of Abbreviations
- TABLE OF TABLES
- Table 1. Philippines Cancer Therapeutics Market Segmentation
- Table 2. List of Vendors
- Table 3. Philippines Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million)
- Table 4. Philippines Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million)
- Table 5. Philippines Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Therapy Types
- Table 6. Philippines Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Therapy Types
- Table 7. Philippines Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Indications
- Table 8. Philippines Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Indications
- Table 9. Philippines Cancer Therapeutics Market – Revenue, 2021–2024 (US$ Million) – by Distribution Channel
- Table 10. Philippines Cancer Therapeutics Market – Revenue Forecast, 2025–2031 (US$ Million) – by Distribution Channel
- Table 11. List of Abbreviations
- TABLE OF FIGURES
- Figure 1. Impact Analysis of Drivers and Restraints
- Figure 2. Philippines Cancer Therapeutics Market Revenue, (US$ Million), 2021–2031
- Figure 3. Heat Map Analysis by Key Players
- Figure 4. Company Positioning and Concentration
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.